Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Several other research firms have also recently weighed in on HUMA. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

HUMA stock opened at $3.09 on Friday. The business’s 50 day moving average price is $4.18 and its two-hundred day moving average price is $4.84. Humacyte has a fifty-two week low of $2.81 and a fifty-two week high of $9.97. The company has a market capitalization of $388.90 million, a price-to-earnings ratio of -2.31 and a beta of 1.36.

Institutional Investors Weigh In On Humacyte

Several hedge funds have recently added to or reduced their stakes in HUMA. Endowment Wealth Management Inc. boosted its stake in shares of Humacyte by 3.6% during the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock worth $526,000 after acquiring an additional 3,590 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Humacyte by 18.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after acquiring an additional 4,327 shares during the last quarter. Beacon Pointe Advisors LLC raised its holdings in Humacyte by 33.3% in the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after acquiring an additional 5,000 shares during the last quarter. Rhumbline Advisers raised its holdings in Humacyte by 4.6% in the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after acquiring an additional 5,005 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Humacyte by 25.3% in the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after acquiring an additional 5,293 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.